evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

8 questions · 8 findings · 3 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3 · 37.5%GRADE not reported 3 · 37.5%Very low 1 · 12.5%Low 1 · 12.5%Moderate 0 · 0%High 0 · 0%

Topical interventions (sucralfate, interferon-alpha, cyclosporin A) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
    Studies not reported
    GRADE not reported

Cyclosporin vs no cyclosporin

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Cyclosporin vs corticosteroids

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Cyclosporin vs intravenous immunoglobulin (IVIG)

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Cyclosporin (systemic; 10 mg/kg/day for 16 weeks) vs Colchicine (systemic; 1 mg daily)

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review